Edivoxetine

Drug Profile

Edivoxetine

Alternative Names: LY-2216684

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eli Lilly
  • Class Antidepressants; Cyclic ethers; Fluorobenzenes; Morpholines; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Attention-deficit hyperactivity disorder
  • Discontinued Major depressive disorder

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Jul 2015 Eli Lilly terminates phase II/III trial in Attention deficit hyperactivity disorder (In children) in USA, Canada, Mexico, Puerto Rico and Taiwan (NCT00965419)
  • 16 Jun 2015 Edivoxetine is still in phase II/III trials for Attention deficit hyperactivity disorder (In children) in the USA, Canada, Mexico, Puerto Rico and Taiwan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top